Clinical Trial Update: Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib [Phase 4]

View source ↗

Summary

Phase IV open-label multicenter study evaluating dasatinib in chronic-phase chronic myeloid leukemia patients who have chronic, low-grade non-hematologic toxici…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Gleevec (Imatinib)
• Sprycel (dasatinib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Chronic Phase Chronic Myeloid Leukemia | Phase 4 | Status: COMPLETED | Results posted: 2016-11-22